Oxidative phosphorylation and cancer: The ongoing warburg hypothesis

Cellular Respiration and Carcinogenesis

Volumn , Issue , 2009, Pages 1-18

  Ristow, Michael ^a   Cuezva, José M ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Cancer; Glycolysis; H+ ATP synthase; Mitochondria; Oxidative phosphorylation

Indexed keywords

EID: 84900169227     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-435-3_1     Document Type: Chapter

References (123)

1. Ristow M. Oxidative metabolism in cancer growth. Curr Opin Clin Nutr Metab Care 2006; 9:339-345
2. Cuezva JM, Sanchez-Arago M, Sala S, Blanco-Rivero A, Ortega AD. A message emerging from development: The repression of mitochondrial beta-F1-ATPase expression in cancer. J Bioenerg Biomembr 2007; 39:259-265
3. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: A scientific statement from the American Heart Association Nutrition Committee. Circulation 2006; 114:82-96
4. Pasteur L. Influence de loxygene sur le developpement de la levure et la fermentation alcoolique. Bulletin de la Societe Chimique de Paris 1861; 79-80
5. Pfeiffer T, Schuster S, Bonhoeffer S. Cooperation and competition in the evolution of ATPproducing pathways. Science 2001; 292:504-507
6. Boyer PD. The ATP synthase. A splendid molecular machine. Annu Rev Biochem 1997; 66:717-749
7. Tovar J, Leon-Avila G, Sanchez LB, et al. Mitochondrial remnant organelles of Giardia function in iron-sulphur protein maturation. Nature 2003; 426:172-176
8. Lill R, Mühlenhoff U. Iron-sulfur-protein biogenesis in eukaryotes. Trends Biochem Sci 2005; 30:133-141
9. Rouault TA, Klausner RD. Iron-sulfur clusters as biosensors of oxidants and iron. Trends Biochem Sci 1996; 21:174-177
10. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15: 2922-2933
11. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281:1309-1312
12. Jaattela M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 2004; 23:2746-2756
13. Warburg O. On the origin of cancer cells. Science 1956; 123:309-314
14. Warburg O. The metabolism of tumours. London: Constable, 1930
15. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124:269-270
16. Warburg O, Posener K, Negelein E. Ü ber den Stoffwechsel der Tumoren [On metabolism of tumors]. Biochemische Zeitschrift 1924; 152:319-344
17. Anonymous. The Nobel prize in physiology or medicine 1931. Available at: Http://nobelprizeorg/medicine/laureates/1931/.
18. Burk D. A colloquial consideration on the Pasteur and Neo-Pasteur effects. Cold Spring Harbor Symposia on Quantitative Biology 1939; 7:420-460
19. Burk D, Schade AL. On respiratory impairment in cancer cells. Science 1956; 124: 270-272
20. Burk D, Woods M. Newer aspects of glucose fermentation in cancer growth and control. Arch Geschwulstforsch 1967; 28:305-319
21. Weinhouse S. On respiratory impairment in cancer cells. Science 1956; 124:267-269
22. Zu XL, Guppy M. Cancer metabolism: Facts, fantasy, and fiction. Biochem Biophys Res Commun 2004; 313:459-465
23. Warburg O. Annual meeting of Nobelists at Lindau, Germany, 1966. English edition by D. Burk. Bethesda, MD: National Cancer Institute. Available at: Http://www.hopeforcancer. com/OxyPlus.htm
24. Krebs H. OttoWarburg: Cell physiologist, biochemist and eccentric. Oxford, UK: Clarendon, 1981
25. Pedersen PL. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978; 22:190-274
26. Cuezva JM, Krajewska M, de Heredia ML, et al. The bioenergetic signature of cancer: A marker of tumor progression. Cancer Res 2002; 62:6674-6681
27. López de Heredia M, Izquierdo JM, Cuezva JM. A conserved mechanism for controlling the translation of beta-F1-ATPase mRNA between the fetal liver and cancer cells. J Biol Chem 2000; 275:7430-7437
28. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004; 84:1014-1020
29. Isidoro A, Martinez M, Fernandez PL, et al. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J 2004; 378:17-20
30. Cuezva JM, Chen G, Alonso AM, et al. The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis 2004; 25: 1157-1163
31. Isidoro A, Casado E, Redondo A, et al. Breast carcinomas fulfill theWarburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 2005; 26:2095-2104
32. López-Ŕos F, Sanchez-Aragó M, Garća- Garća E, et al. Loss of the mitochondrial bioenergetic capacity underlies the glucosa avidity of carcinomas. Cancer Res 2007; 67:9013-9017
33. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science 1987; 235:1495-1498
34. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235:1492-1495
35. Shim H, Dolde C, Lewis BC, et al. c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth. Proc Natl Acad Sci USA 1997; 94:6658-6663
36. Ziegler A, von Kienlin M, Decorps M, Remy C. High glycolytic activity in rat glioma demonstrated in vivo by correlation peak 1H magnetic resonance imaging. Cancer Res 2001; 61:5595-5600
37. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23:1641-1674
38. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2:683-693
39. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004; 4:891-899
40. Raghunand N, Gatenby RA, Gillies RJ. Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 2003; 76(Spec No 1):S11-22
41. Grover-McKay M, Walsh SA, Seftor EA, Thomas PA, Hendrix MJ. Role for glucose transporter 1 protein in human breast cancer. Pathol Oncol Res 1998; 4:115-120
42. Sakashita M, Aoyama N, Minami R, et al. Glut1 expression in T1 and T2 stage colorectal carcinomas: Its relationship to clinicopathological features. Eur J Cancer 2001; 37:204-209
43. Younes M, Lechago LV, Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res 1996; 2:1151-1154
44. Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000; 275:21797-21800
45. Govindarajan B, Shah A, Cohen C, et al. Malignant transformation of human cells by constitutive expression of platelet-derived growth factor-BB. J Biol Chem 2005; 280: 13936-13943
46. Dang CV, Lewis BC, Dolde C, Dang G, Shim H. Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J Bioenerg Biomembr 1997; 29:345-354
47. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12:5447-5454
48. Robey IF, Lien AD,Welsh SJ, Baggett BK, Gillies RJ. Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 2005; 7:324-330
49. Ebert BL, Firth JD, Ratcliffe PJ. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct cis-Acting sequences. J Biol Chem 1995; 270: 29083-29089
50. Firth JD, Ebert BL, Ratcliffe PJ. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem 1995; 270:21021-21027
51. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994; 269:23757-23763
52. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94:8104-8109
53. Semenza GL. HIF-1, O(2), and the 3 PHDs: How animal cells signal hypoxia to the nucleus. Cell 2001; 107:1-3
54. Semenza GL. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 2007; 39:231-234
55. McKusick VA, Kniffin CL, Tiller GE, et al. Online Mendelian Inheritance in Man: Von Hippel-Lindau syndrome (OMIM 193300). Available at: Http://www.ncbi.nlm.nih.gov/ entrez/dispomim.cgi?.id=193300
56. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-Associated stroma. Neoplasia 2005; 7:1-6
57. Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS, Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 2005; 280:41928-41939
58. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factorindependent survival. Mol Cell Biol 2003; 23:7315-7328
59. Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64:3892-3899
60. Govindarajan B, Sligh JE, Vincent BJ, et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 2007; 117:719-729
61. Pedersen PL. Warburg, me and hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers-most common phenotypes, the Warburg Effect, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 2007; 39:211-222
62. Bustamante E, Morris HP, Pedersen PL. Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem 1981; 256:8699-8704
63. Mathupala SP, Heese C, Pedersen PL. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 1997; 272:22776-22780
64. Smith TA, Sharma RI, Thompson AM, Paulin FE. Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. J Nucl Med 2006; 47:1525-1530
65. Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126:107-120
66. Hervouet E, Demont J, Pecina P, et al. A new role for the von Hippel-Lindau tumor suppressor protein: Stimulation of mitochondrial oxidative phosphorylation complex biogenesis. Carcinogenesis 2005; 26:531-539
67. Wu M, Neilson A, Swift AL, et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol 2007; 292:C125-136
68. Hoberman HD. Is there a role for mitochondrial genes in carcinogenesis?. Cancer Res 1975; 35:3332-3335
69. Baggetto LG. Role of mitochondria in carcinogenesis. Eur J Cancer 1992; 29A:156-159
70. Carew JS, Huang P. Mitochondrial defects in cancer. Mol Cancer 2002; 1:9
71. Petros JA, Baumann AK, Ruiz-Pesini E, et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA 2005; 102:719-724
72. Singh KK. Mitochondrial dysfunction is a common phenotype in aging and cancer. Ann N Y Acad Sci 2004; 1019:260-264
73. Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease. Nat Rev Genet 2005; 6:389-402
74. Herrmann PC, Herrmann EC. Oxygen metabolism and a potential role for cytochrome c oxidase in the Warburg effect. J Bioenerg Biomembr 2007; 39:247-250
75. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287:848-851
76. Habano W, Sugai T, Nakamura S, Uesugi N, Higuchi T, Terashima M, Horiuchi S. Reduced expression and loss of heterozygosity of the SDHD gene in colorectal and gastric cancer. Oncol Rep 2003; 10:1375-1380
77. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004; 292:943-951
78. Deml E, Oesterle D, Wolff T, Greim H. Age-, sex-, and strain-dependent differences in the induction of enzyme-Altered islands in rat liver by diethylnitrosamine. J Cancer Res Clin Oncol 1981; 100:125-134
79. Racker E. Bioenergetics and the problem of tumor growth. Am Sci 1972; 60:56-63
80. Racker E, Spector M. Warburg effect revisited: Merger of biochemistry and molecular biology. Science 1981; 213:303-307
81. Lehninger AL. Biochemistry. New York: Worth Publishers, 1970.
82. Shin YK, Yoo BC, Chang HJ, et al. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 2005; 65: 3162-3170
83. Santamaria G, Martinez-Diez M, Fabregat I, Cuezva JM. Efficient execution of cell death in non-glycolytic cells requires the generation of ROS controlled by the activity of mitochondrial H+-ATP synthase. Carcinogenesis 2006; 27:925-935
84. Zhou S, Kachhap S, Singh KK. Mitochondrial impairment in p53-deficient human cancer cells. Mutagenesis 2003; 18:287-292
85. Ma W, Sung HJ, Park JY, Matoba S, Hwang PM. A pivotal role for p53: Balancing aerobic respiration and glycolysis. J Bioenerg Biomembr 2007; 39:243-246
86. Matoba S, Kang JG, Patino WD, et al. p53 regulates mitochondrial respiration. Science 2006; 312:1650-1653
87. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3:177-185
88. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006; 3:187-197
89. Pelicano H, Xu RH, Du M, et al. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol 2006; 175:913-923
90. Stiles B, Groszer M, Wang S, Jiao J, Wu H. PTENless means more. Dev Biol 2004; 273: 175-184
91. Martinez-Diez M, Santamaria G, Ortega AD, Cuezva JM. Biogenesis and dynamics of mitochondria during the cell cycle: Significance of 3-UTRs. PLoS ONE 2006; 1:e107
92. Wang T, Marquardt C, Foker J. Aerobic glycolysis during lymphocyte proliferation. Nature 1976; 261:702-705
93. Chen Z, Odstrcil EA, Tu BP, McKnight SL. Restriction of DNA replication to the reductive phase of the cell cycle protects genome integrity. Science 2007; 316:1916-1919
94. Sakamaki T, Casimiro MC, Ju X, et al. Cyclin d1 determines mitochondrial function in vivo. Mol Cell Biol 2006; 26:5449-5469
95. Wang C, Li Z, Lu Y, et al. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. Proc Natl Acad Sci USA 2006; 103:11567-11572
96. Luis AM, Izquierdo JM, Ostronoff LK, Salinas M, Santarén JF, Cuezva JM. Translational regulation of mitochondrial differentiation in neonatal rat liver. Specific increase in the translational efficiency of the nuclear-encoded mitochondrial beta-F1-ATPase mRNA. J Biol Chem 1993; 268:1868-1875
97. Izquierdo JM, Ricart J, Ostronoff LK, Egea G, Cuezva JM. Changing patterns of transcriptional and post-Transcriptional control of beta-F1-ATPase gene expression during mitochondrial biogenesis in liver. J Biol Chem 1995; 270:10342-10350
98. Izquierdo JM, Cuezva JM. Control of the translational efficiency of beta-F1-ATPase mRNA depends on the regulation of a protein that binds the 3 untranslated region of the mRNA. Mol Cell Biol 1997; 17:5255-5268
99. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70
100. Ristow M, Pfister MF, Yee AJ, et al. Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc Natl Acad Sci USA 2000; 97:12239-12243
101. Schulz TJ, Thierbach R, Voigt A, et al. Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J Biol Chem 2006; 281:977-981
102. Mühlenhoff U, Richhardt N, Ristow M, Kispal G, Lill R. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum Mol Genet 2002; 11:2025-2036
103. Thierbach R, Schulz TJ, Isken F, et al. Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span, and tumor growth in mice. Hum Mol Genet 2005; 14:3857-3864
104. Bulavin DV, Fornace AJ Jr. p38 MAP kinase-s emerging role as a tumor suppressor. Adv Cancer Res 2004; 92:95-118
105. Timofeev O, Lee TY, Bulavin DV. A subtle change in p38 MAPK activity is sufficient to suppress in vivo tumorigenesis. Cell Cycle 2005; 4:118120
106. Bi X, Lin Q, Foo TW, et al. Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: Mechanism of tumorigenesis. Mol Cell Proteomics 2006; 5:1119-1130
107. Dey R, Moraes CT. Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells. J Biol Chem 2000; 275:7087-7094
108. Kim JY, Kim YH, Chang I, et al. Resistance of mitochondrial DNA-deficient cells to TRAIL: Role of Bax in TRAIL-induced apoptosis. Oncogene 2002; 21:3139-3148
109. Park SY, Chang I, Kim JY, et al. Resistance of mitochondrial DNA-depleted cells against cell death: Role of mitochondrial superoxide dismutase. J Biol Chem 2004; 279: 7512-7520
110. Tomiyama A, Serizawa S, Tachibana K, et al. Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors Bax and Bak. J Natl Cancer Inst 2006; 98:1462-1473
111. Matsuyama S, Xu Q, Velours J, Reed JC. The mitochondrial F0F1-ATPase proton pump is required for function of the proapoptotic protein Bax in yeast and mammalian cells. Mol Cell 1998; 1:327-336
112. Gross A, Pilcher K, Blachly-Dyson E, et al. Biochemical and genetic analysis of the mitochondrial response of yeast to BAX and BCL-X(L). Mol Cell Biol 2000; 20:3125-3136
113. Harris MH, Vander Heiden MG, Kron SJ, Thompson CB. Role of oxidative phosphorylation in Bax toxicity. Mol Cell Biol 2000; 20:3590-3596
114. Plas DR, Thompson CB. Cell metabolism in the regulation of programmed cell death. Trends Endocrinol Metab 2002; 13:75-78
115. Danial NN, Gramm CF, Scorrano L, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 2003; 424:952-956
116. Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V. In self-defence: Hexokinase promotes voltage-dependent anion channel closure and prevents mitochondriamediated apoptotic cell death. Biochem J 2004; 377:347-355
117. Vahsen N, Cande C, Briere JJ, et al. AIF deficiency compromises oxidative phosphorylation. EMBO J 2004; 23:4679-4689
118. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-Activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1:15-25
119. Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu Rev Biochem 2006; 75:137-163
120. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115:577-590
121. Reznick RM, Shulman GI. The role of AMP-Activated protein kinase in mitochondrial biogenesis. J Physiol 2006; 574:33-39
122. Shaw RJ. Glucose metabolism and cancer. Curr Opin Cell Biol 2006; 18:598-608
123. Jones RG, Plas DR, Kubek S, et al. AMP-Activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005; 18:283-293